Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520053 | 0.91 | EGFR (0.56) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL8796440 | 0.88 | EGFR (0.53) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL7520151 | 0.88 | EGFR (0.53) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL8825686 | 0.87 | EGFR (0.52) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL8825801 | 0.86 | MAPK1 (0.64) | EGFRMAPK1ABCG2ALDH1A1HPGD | |
| SCHEMBL7526231 | 0.86 | EGFR (0.52) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL8795549 | 0.86 | EGFR (0.52) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL8796538 | 0.86 | EGFR (0.52) | EGFRMAPK1PDGFRBABCG2ALDH1A1 | |
| SCHEMBL8825839 | 0.85 | EGFR (0.62) | EGFRMAPK1HPGDHTTKDM4E | |
| SCHEMBL8796546 | 0.85 | EGFR (0.51) | EGFRMAPK1PDGFRBABCG2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6127541-A | 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0863144-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | Kyowa Hakko Co., Ltd. (JP) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | MKI67, HRAS, VHL | EGFR 3583/4885MAPK1 1224/4885PDGFRB 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.